PsA Improvement Thresholds Vary by Baseline Disease Activity, Not Prior TNFi Exposure

Refining Treatment Targets in Psoriatic Arthritis

Psoriatic arthritis (PsA) is a complex, immune-mediated inflammatory disease with diverse manifestations including joint inflammation, enthesitis, dactylitis, and skin psoriasis [1]. Because untreated PsA can lead to irreversible joint destruction and substantially impair quality of life and work productivity, effective management is essential [2, 3]. Biologic therapies, particularly interleukin (IL)-23 inhibitors like guselkumab, have demonstrated robust efficacy across multiple disease domains [4, 5, 6]. Despite these advances, a persistent clinical challenge is defining what constitutes a meaningful improvement for an individual patient [7, 8]. The concept of minimal clinically important improvement (MCII) provides a threshold for this, guiding personalized treatment goals and the interpretation of clinical trial data [9]. A recent analysis offers new data on how these crucial thresholds vary among different patient populations with PsA.

Investigating Personalized Improvement Goals

To address the variability in PsA presentation and treatment response, a new study sought to determine if treatment goals should be more personalized. The central objective was to calculate the minimal clinically important improvement (MCII) thresholds for key PsA outcome measures. An MCII threshold is defined as the smallest change in a score that a patient perceives as beneficial, making it a more patient-centric benchmark than statistical significance alone. The investigators specifically examined how these thresholds might differ based on two clinically relevant factors: a patient's treatment history, particularly prior exposure to tumor necrosis factor inhibitors (TNFi), and their disease activity at the start of treatment. Establishing such nuanced efficacy thresholds is critical not only for interpreting the results of randomized clinical trials but also for implementing effective treat-to-target strategies and facilitating shared decision-making in routine clinical practice.

Study Design and Outcome Measures

This investigation was conducted as a post hoc analysis, a method that involves re-examining data after a study has concluded to answer new questions. The researchers pooled data from three large randomized clinical trials involving participants with active psoriatic arthritis (PsA). In these trials, patients received either guselkumab every 8 weeks (Q8W) or a placebo, with the placebo group crossing over to receive guselkumab at Week 24. To calculate the MCII thresholds, the analysis utilized established distribution-based methods, which are statistical techniques that define a meaningful change based on the variability of the outcome measure within the study population. The assessment covered both clinician-rated and patient-reported outcomes, including the clinical Disease Activity Index for PsA (cDAPSA), the PsA Disease Activity Score (PASDAS), and patient assessments of arthritis, psoriasis, pain, fatigue, and physical function. For a more detailed analysis, participants were stratified into subgroups based on their prior TNFi treatment status and their baseline disease activity, which was categorized as either high or moderate using cDAPSA and PASDAS scores.

Baseline Disease Activity Influences Improvement Thresholds

The analysis revealed that the bar for meaningful improvement is not uniform across all patients. While prior treatment history did not appear to influence patient perception, baseline disease severity did. Specifically, estimated MCII thresholds for all examined measures were consistent across both tumor necrosis factor inhibitor (TNFi)-experienced and biologic-naïve cohorts. This suggests that a patient's prior exposure to a TNFi biologic does not alter the degree of improvement they perceive as clinically important. In contrast, a significant distinction emerged based on initial disease activity. The study found that the MCII for the clinical Disease Activity Index for PsA (cDAPSA) was more stringent for participants who started with high disease activity compared to those with moderate disease activity. In practical terms, patients with more severe initial joint disease required a larger absolute improvement in their cDAPSA score to report a meaningful benefit. This effect was specific to the cDAPSA, a composite score heavily weighted toward joint counts; the MCII for the PsA Disease Activity Score (PASDAS) did not differ between high and moderate baseline activity groups. These findings indicate that disease severity at the outset may directly impact a patient's perception of improvement.

Guselkumab Efficacy and Threshold Validity

To ensure the newly calculated MCII thresholds were clinically meaningful, the researchers tested whether they could effectively measure the impact of an active therapy. The results showed that guselkumab-treated participants had significantly greater odds of achieving these MCII thresholds compared to placebo-treated participants as early as Week 8. This rapid and superior response was consistent regardless of a patient's prior TNFi exposure or their baseline disease activity as measured by either cDAPSA or PASDAS scores. This consistent performance of guselkumab across different patient subgroups serves an important secondary purpose: it supports the known-groups validity of the estimated MCII thresholds. Known-groups validity is a way of confirming that a measurement tool, in this case the MCII thresholds, can accurately distinguish between groups that are expected to perform differently (e.g., an active treatment group versus a placebo group). This confirmation reinforces the reliability of these thresholds for use in both clinical trials and patient care.

Clinical Implications for Practice

The findings from this analysis have direct implications for managing PsA in the clinic. The key takeaway is that while prior TNFi exposure does not seem to alter a patient's perception of improvement, the MCII threshold was greater for participants with higher baseline joint disease activity as measured by cDAPSA. This suggests that clinicians may need to calibrate treatment goals and patient expectations based on initial disease severity. For a patient presenting with high disease activity, a larger absolute reduction in their cDAPSA score may be necessary to achieve what they consider a meaningful clinical benefit. This insight can refine shared decision-making, allowing for more personalized discussions about treatment targets. It also adds a layer of nuance to treat-to-target strategies, suggesting that the target itself might be interpreted differently depending on the patient's starting point. Ultimately, by providing a more granular understanding of what constitutes meaningful improvement, these findings can help clinicians better interpret therapeutic responses and tailor management plans to individual patient characteristics.

References

1. Firdous S, Amjad H, Choudhary MU, Afzal MW, Tayyab RH, Parveen A. Emerging biological therapies for psoriatic arthritis: A systematic review.. Medicine. 2025. doi:10.1097/MD.0000000000045259

2. Gossec L, Humphries B, Rutherford M, Taieb V, Willems D, Tillett W. Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis.. Arthritis research & therapy. 2024. doi:10.1186/s13075-024-03282-0

3. Haberman RH, MacFarlane KA, Catron S, et al. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial.. BMJ open. 2022. doi:10.1136/bmjopen-2022-063650

4. Huang X, Shentu H, He Y, et al. Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials. Immunologic Research. 2023. doi:10.1007/s12026-023-09366-4

5. Dodero-Anillo JM, Fernandez-Pujol-Marzo M, Martínez MJS, Ruíz‐Villaverde R, Armario-Hita J. Efficacy and Safety of Guselkumab in Real-World Evidence: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2026. doi:10.3390/jcm15103692

6. Mease P, Mcinnes I, Tam L, et al. AB0896 Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Updates to a Systematic Literature Review and Network Meta-Analysis. Annals of the Rheumatic Diseases. 2022. doi:10.1136/annrheumdis-2022-eular.1775

7. Zardin-Moraes M, Silva ALFAD, Saldanha CF, et al. Prevalence of Psoriatic Arthritis Patients Achieving Minimal Disease Activity in Real-world Studies and Randomized Clinical Trials: Systematic Review with Metaanalysis. The Journal of Rheumatology. 2019. doi:10.3899/jrheum.190677

8. Curtis JR, Deodhar A, Soriano ER, et al. Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials.. Rheumatology and therapy. 2024. doi:10.1007/s40744-024-00702-0

9. Vyas J, Johns J, Ali FM, et al. A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad079